Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs Mesoblast Limited — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $27.49, while Mesoblast Limited trades at $16.08 (market cap $2.17B). Which is the better fit depends on your goals.
| KOLD | MESO | |
|---|---|---|
Sector | Leveraged / Inverse | Technology |
52-Week High | $49.39 | $20.96 |
52-Week Low | $13.58 | $12.88 |
Market Cap | — | $2.17B |
Enterprise Value | — | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD trades at $28.25, up 4.01% today, with a bullish technical signal from moving averages and strong trend strength indicated by ADX. Recent news highlights natural gas market volatility driven by weather forecasts and storage reports, with the ETF positioned as a tactical trading tool amid price swings around $3/MMBtu (Seeking Alpha, 2026-06-08).
The outlook remains tied to natural gas price movements, with opportunities for short-term gains from volatility but risks from weather-dependent demand shifts and production levels. Investors face commodity price exposure and leverage risks inherent in inverse ETFs.
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
